How Trunome is Revolutionizing Chronic Disease Diagnosis in India

Trunome is a startup based in Chennai, founded by Agragesh Ramani and Avinash Ramani. They have developed a patented technology that enables early diagnosis and monitoring of chronic diseases, including cancer recurrence, through blood tests. Their vision is to impact over one billion people and improve their physical, mental, and emotional well-being through this technology. They have tested over 5000 samples and have partnerships with six hospitals in India.

AIM OF THE STARTUP

Trunome is a healthcare startup founded by Agragesh Ramani and Avinash Ramani with the aim to address the challenges faced by patients suffering from chronic diseases, such as organ transplant recipients. With the increasing number of patients, it is becoming more challenging to monitor their post-transplant processes, which is not only painful but also expensive and risky.

To solve these problems, Trunome has developed a patented technology that can detect and monitor chronic diseases through blood tests with 100% accuracy. This technology can diagnose chronic diseases at an early stage, which can lead to better treatment outcomes and improved quality of life for patients. They have also received a US patent and have been cleared by CDSCO.

Trunome has already impacted over 1500 lives through testing more than 5000 samples and has tied up with six leading hospitals in India. Their vision is to impact over one billion people through their innovative technology, improve their quality of life, and assure their physical, mental, and emotional well-being.

Avinash's scientific background and expertise in molecular biology, coupled with Agragesh's business acumen, have helped Trunome to create a unique and revolutionary solution to a critical problem faced by the healthcare industry.

TARGET MARKET AND BUSINESS MODEL

Trunome's target market comprises patients suffering from chronic diseases, especially those who have undergone organ transplants, in India. The startup's technology can help diagnose and monitor chronic diseases at an early stage, leading to better treatment outcomes and improved quality of life for patients. With the increasing number of patients suffering from chronic diseases, Trunome has identified a significant market opportunity in India.

Trunome's business model is based on a B2B approach, where they partner with hospitals and healthcare providers to offer their diagnostic services. They have already tied up with six leading hospitals in India and aim to expand their network further to reach a larger patient base. The startup generates revenue through the fees charged for their diagnostic services, which is expected to grow as they expand their reach and impact more patients.

Trunome's patented technology, coupled with their partnership with hospitals and healthcare providers, creates a compelling value proposition for patients, healthcare providers, and the startup itself. By providing accurate and reliable diagnostic services to patients, Trunome is addressing a critical need in the healthcare industry and is well-positioned for growth in the Indian market.

FUNDING IN SHARK TANKS INDIA

The owners asked for 1.5 crores rupees for 1% equity in the company at a valuation of 150 crores.

During the negotiations, Peyush offered 1.5 crores for 2% equity, while Anupam offered 1.5 crores for 1.75% equity. Veenita offered 75 lakhs for 1% equity and 75 lakhs interest-free debt. In the end, all four sharks gave a combined offer of 1.5 crores for 2% equity.

However, the owners of Trunome gave a counteroffer of 3 crores for 2.5% equity, which the sharks ultimately accepted. The final deal was closed with Peyush, Anupam, Veenita, and Aman investing 1.5 crores for 2% equity in the company.

Trunome's successful appearance on Shark Tank India is a testament to the startup's promising future in the healthcare industry. With the funding secured from the sharks, Trunome can further develop their innovative technology and expand their reach, impacting more patients suffering from chronic diseases in India.